Worcester RNAi therapeutics firm
RXi Pharmaceuticals Corp. has won a total of almost $580,000
from two Small Business Innovation Research grants awarded through
the National Institutes of Health.
The National Institute of Neurological Disorders and Stroke offered
the first grant, for $304,559, to address Phase 1 of a project
aimed at developing RNAi treatment for amyotrophic lateral
sclerosis (ALS) and other neurodegenerative disorders. A news
release today noted that RXi can apply for more funding to move the
project into Phase 2.